GlucoTrack, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Erik Emerson
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 301 Route 17 North Rutherford NJ United States of America 07070
- IPO Date
- Apr 25, 2013
- CIK
- 0001506983
- Website
- glucotrack.com
- Similar Companies
- Business
- GlucoTrack, Inc. (Nasdaq: GCTK) develops and commercializes novel implantable technologies for continuous blood glucose monitoring to improve glycemic management for people living with diabetes; its primary product candidate is a fully implantable continuous blood glucose monitor (CBGM) featuring a sensor longevity of three years, real-time blood glucose measurement from the subclavian vein, no external wearable components, and minimal calibration requirements. The company, founded in 2001 and headquartered in Rutherford, New Jersey, previously known as Integrity Applications, Inc. until its rebranding in November 2021, targets Type 1 and insulin-dependent Type 2 diabetes patients with its investigational CBGM system, which has advanced through preclinical animal studies, a first human clinical study demonstrating safety and accuracy, and ongoing preparations for multicenter feasibility trials in Australia and a U.S. pilot study pending FDA Investigational Device Exemption approval in late 2025. Recent developments include securing $16.3 million in funding proceeds from November 2024 through March 2025 to support clinical milestones, repurchasing over 90% of its Series A Warrants in June 2025 as part of capital structure optimization following a $10 million public offering, achieving ISO 13485:2016 certification for medical device quality standards, expanding research into epidural glucose monitoring applications, strengthening its leadership and advisory boards with key appointments in clinical, regulatory, and financial expertise, and presenting clinical data at major conferences such as ATTD 2025.
Company News
Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent
Glucotrack Announces $11.5 Million Financing
Glucotrack Announces $11.5 Million Financing
Glucotrack, Inc. Announces Reverse Stock Split
Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation
E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack
Glucotrack Announces $5.5 Million Financing
Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline
Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration
E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing
Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights